@article{article, title  = {{372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer}},

 publisher = {{Elsevier BV}},

 url = {{https://doi.org/10.1136/ijgc-2020-igcs.322 }},

 year = {{2020}},

 month = {{11}},

 author = {{Santin A and Vergote I and Martín A and Moore K and Oaknin A and Romero I and Diab S and Copeland LJ and Monk B and Coleman R and Herzog TJ et al}},

 doi = {{10.1136/ijgc-2020-igcs.322}},

 volume = {{30}},

 journal = {{International Journal of Gynecological Cancer}},

 pages = {{A154-A154}},

 note = {{Accessed on 2026/10/23}}}